Elobact

• Anti-bacterial Agents
• Cephalosporins
• ATC:J01DC02

• Ancef
• Biofuroksym
• Ceclor
• Ceclor CD
• Cedax
• Cefditoren
• Cefizox
• Cefobid
• Cefotan
• Ceftin
• Cefurax
• Cefuril
• Cefuroxim
• Cefuroxime [USAN:BAN:INN]
• Cefuroximo [INN-Spanish]
• Cefuroximum [INN-Latin]
• Cefzil
• Cepazine
• Cephuroxime
• Ceptaz
• Duricef
• Elobact
• Fortaz
• Keflex
• Keftab
• Kefurox
• Kefzol
• Kerurox
• Mandol
• Maxipime
• Mefoxin
• Monocid
• Omnicef
• Oraxim
• Rocephin
• Sharox
• Tazicef
• Vantin
• Velosef
• Zinacef
• Zinacef Danmark
• Zinat
• Zinnat

• No information avaliable

C₁₆H₁₆N₄O₈S

http://www.rxlist.com/cgi/generic/cefurox.htm

Elobact FDA

Elobact MSDS

M. C. Cook et al., U.S. Pat. 4,267,320 (1977)

424.386 g/mol

218-225 ^oC

Freely soluble as sodium salt (145 mg/L)

Solid

-0.921

Powder; Powder for oral suspension; Tablet (125, 250, or 500 mg)

For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.

Cefuroxime is a β-lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi.

Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).

Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.

Patients should be counseled that antibacterial drugs including Cefuroxime for Injection USP and Dextrose Injection USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefuroxime for Injection USP and Dextrose Injection USP is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefuroxime for Injection USP and Dextrose Injection USP or other antibacterial drugs in the future.

Enteric bacteria and other eubacteria